Abstract
BackgroundApremilast (APR), an oral small molecule specific inhibitor of phosphodiesterase 4, works intracellularly to modulate inflammatory mediators. The PALACE 1, 2 and 3 trials compared APR efficacy and safety vs...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have